Tumor Antigen Heterogeneity: The "Elephant in the Room" of Adoptive T-cell Therapy for Solid Tumors

Steven M Albelda1

  • 1Department of Medicine, Division of Pulmonary, Allergy, and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. albelda@pennmedicine.upenn.edu.

A major hurdle to the efficacy of adoptive cell therapy and chimeric antigen receptors T-cell therapy is the choice of antigen(s) to target. An article in this issue addresses this by capitalizing on the synergistic effect of pathogen-based immunotherapy and adoptive cell therapy that results in epitope/antigen spreading and enhancement of the endogenous T-cell response against antigens not originally targeted.See article by Xin et al., p. 7.

Related Concept Videos